Microplasmin may eliminate need for surgery

Article

Microplasmin, the drug aimed at patients with focal vitreomacular adhesion, is to be trialled at Southampton General Hospital. Injected directly into the eye earlier clinical studies have indicated that it has potential to be effective without the risks associated with surgery.

Microplasmin, the drug aimed at patients with focal vitreomacular adhesion, is to be trialled at Southampton General Hospital. Injected directly into the eye earlier clinical studies have indicated that it has potential to be effective without the risks associated with surgery.

The work has been spearheaded by Professor of Ophthalmology at the University of Southampton and consultant ophthalmologist at Southampton Eye Unit, Andrew Lotery and will be trialled at the Wellcome Trust Clinical Research Facility (WTCRF). "Southampton Eye Unit has worked with Wellcome Trust research nurses in 24 studies over the last six years," he said. "This has led to significant research breakthroughs and many patients have had their sight saved by being enrolled in our studies. My research programme would not be possible without the WTCRF."

Director of the WTCRF Dr Saul Faust said: "It is fantastic that the centre is able to support ground breaking research such as Andrew's that has such a positive impact on patient care."

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.